Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients with COVID-19 (BIRCH): a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study.
Streinu-Cercel A, Castagna A, Chang SC, Chen YS, Koullias Y, Mozaffarian A, Hyland RH, Humeniuk R, Caro L, Davies S, Rodriguez L, Hedskog C, Chen S, Etchevers K, Behenna-Renton N, Llewellyn J, Osinusi A, Duff F, Barrat Hernández A, McNally D, Simon-Campos JA, Leal FE, Fouche LF, González Del Castillo JM. Streinu-Cercel A, et al. Among authors: mozaffarian a. Clin Infect Dis. 2025 Jul 22:ciaf406. doi: 10.1093/cid/ciaf406. Online ahead of print. Clin Infect Dis. 2025. PMID: 40694627
Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study.
Ogbuagu O, Goldman JD, Gottlieb RL, Singh U, Shinkai M, Acloque G, Fusco DN, Gonzalez E, Kumar P, Luetkemeyer A, Lichtman A, Mozaffarian A, Koullias Y, Hyland RH, Llewellyn J, Osinusi A, Duff F, Humeniuk R, Caro L, Davies S, Rodriguez L, Hedskog C, Chen S, Etchevers K, Nadig P, Kohli A; OAKTREE Trial Investigators. Ogbuagu O, et al. Among authors: mozaffarian a. Lancet Infect Dis. 2025 Dec;25(12):1282-1292. doi: 10.1016/S1473-3099(25)00238-5. Epub 2025 Jul 14. Lancet Infect Dis. 2025. PMID: 40675167 Clinical Trial.
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study.
Werth VP, Fleischmann R, Robern M, Touma Z, Tiamiyu I, Gurtovaya O, Pechonkina A, Mozaffarian A, Downie B, Matzkies F, Wallace D. Werth VP, et al. Among authors: mozaffarian a. Rheumatology (Oxford). 2022 May 30;61(6):2413-2423. doi: 10.1093/rheumatology/keab685. Rheumatology (Oxford). 2022. PMID: 34498056 Free PMC article. Clinical Trial.
Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study.
Price E, Bombardieri M, Kivitz A, Matzkies F, Gurtovaya O, Pechonkina A, Jiang W, Downie B, Mathur A, Mozaffarian A, Mozaffarian N, Gottenberg JE. Price E, et al. Among authors: mozaffarian a. Rheumatology (Oxford). 2022 Nov 28;61(12):4797-4808. doi: 10.1093/rheumatology/keac167. Rheumatology (Oxford). 2022. PMID: 35377447 Free PMC article. Clinical Trial.